MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...

MB-105, a CD5-targeted CAR-T cell therapy, has received FDA regenerative medicine advanced therapy designation for relapsed/refractory CD5-positive T-cell lymphoma. The designation aims to expedite ...

100% complete response rate achieved in primary cohort with acceptable safety profile in relapsed/refractory T-cell lymphoma patients HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- March Biosciences ...

Please provide your email address to receive an email when new articles are posted on . CD5 knockout CAR-T exhibited efficacy in several preclinical models. A phase 1 trial will evaluate the approach ...

A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL). This is an ASCO Meeting Abstract from the ...

PHILADELPHIA, PA — Vittoria Biotherapeutics, Inc. announced it will present interim clinical data from its first-in-human Phase 1 study of VIPER-101, a CD5-modulated autologous CAR-T therapy, at the ...

Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital have developed a chimeric antigen receptor (CAR) T cell ...

Please provide your email address to receive an email when new articles are posted on . Multiple studies published since this summer suggest chimeric antigen receptor T-cell therapies are comparably ...

The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on ...

CD5 immunohistochemistry (IHC) was performed on 404 DLBCLs to identify CD5 IHC+ and CD5 IHC– cases, which were subsequently characterized at the molecular level through mutational and transcriptional ...